In patients with prior myocardial infarction and elevated CRP, the IL-1β inhibitor, canakinumab, reduced cardiovascular event risk and the levels of IL-6 and CRP but did not affect LDL cholesterol and showed a small increase in fatal infections. Here, CRP is linked to infection.